Jim Simons Hepion Pharmaceuticals, Inc. Transaction History

Renaissance Technologies LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.31 - $1.06 $11,997 - $41,022	38,700 Added 15.76%	284,300 $221,000
Q4 2022 Feb 13, 2023	BUY	$0.27 - $11.9 $3,645 - $160,650	13,500 Added 5.82%	245,600 $74,000
Q3 2022 Nov 14, 2022	SELL	$0.51 - $10.4 $1,275 - $26,000	-2,500 Reduced 1.07%	232,100 $117,000
Q2 2022 Aug 12, 2022	BUY	$0.57 - $1.22 $61,559 - $131,760	108,000 Added 85.31%	234,600 $134,000
Q1 2022 May 13, 2022	BUY	$0.93 - $1.29 $70,959 - $98,427	76,300 Added 151.69%	126,600 $163,000
Q4 2021 Feb 11, 2022	BUY	$1.14 - $1.58 $57,341 - $79,474	50,300 New	50,300 $57,000
Q2 2021 Aug 13, 2021	SELL	$1.56 - $2.26 $245,700 - $355,949	-157,500 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$1.77 - $2.98 $303,593 - $511,135	-171,522 Reduced 52.13%	157,500 $290,000
Q4 2020 Feb 10, 2021	BUY	$1.58 - $3.64 $519,854 - $1.2 Million	329,022 New	329,022 $721,000
Q1 2020 May 14, 2020	SELL	$1.15 - $5.74 $49,494 - $247,043	-43,039 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$2.25 - $6.99 $96,837 - $300,842	43,039 New	43,039 $231,000

Ticker HEPA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,229,600
Market Cap $51.8M
Description
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.